See more : ScION Tech Growth II (SCOBU) Income Statement Analysis – Financial Results
Complete financial analysis of Addex Therapeutics Ltd (ADXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Addex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vision Energy Corp (VENG) Income Statement Analysis – Financial Results
- Bestway Global Holding Inc. (3358.HK) Income Statement Analysis – Financial Results
- KP Tissue Inc. (KPTSF) Income Statement Analysis – Financial Results
- Modison Limited (MODISONLTD.NS) Income Statement Analysis – Financial Results
- China Television Company, Ltd. (9928.TW) Income Statement Analysis – Financial Results
Addex Therapeutics Ltd (ADXN)
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M | 499.89K | 17.33K | 40.30K | 85.40K | 91.76K | 121.09K | 2.82M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Cost of Revenue | 6.94M | 14.62M | 12.82M | 10.37M | 230.10K | 144.17K | 29.76K | 17.33K | 40.30K | 85.40K | 91.76K | 1.27M | 27.99M | 31.16M | 0.00 | 0.00 | -156.03K | 0.00 |
| Gross Profit | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | 5.90M | 470.13K | 0.00 | 0.00 | 0.00 | 0.00 | -1.15M | -25.16M | -29.19M | 4.09M | 26.81M | 642.96K | 4.74M |
| Gross Profit Ratio | -329.99% | -928.06% | -339.55% | -187.12% | 91.67% | 97.61% | 94.05% | 0.00% | 0.00% | 0.00% | 0.00% | -948.14% | -891.19% | -1,477.75% | 100.00% | 100.00% | 132.04% | 100.00% |
| Research & Development | 2.75M | 14.67M | 12.84M | 10.37M | 12.45M | 2.37M | 841.31K | 819.33K | 761.22K | 258.06K | 2.22M | 4.76M | 4.76M | 31.16M | 39.96M | 44.19M | 12.21M | 9.77M |
| General & Administrative | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Other Expenses | 1.94M | -22.52K | 444.00K | 336.68K | 648.17K | 382.99K | 197.67K | 799.70K | 311.82K | -9.44K | 5.77M | 9.40M | -919.55K | -2.02M | 0.00 | -67.33K | 25.90M | 15.98M |
| Operating Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 5.81M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Cost & Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 33.80M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Interest Income | 63.96K | 29.25K | 5.32K | 35.31K | 36.87K | 85.87K | 0.00 | 27.00 | 39.86K | 1.59K | 4.13K | 22.66K | 72.20K | 97.25K | 362.13K | 3.31M | 2.55M | 241.99K |
| Interest Expense | 21.61K | 48.90K | 63.01K | 69.50K | 128.52K | 220.17K | 45.35K | 6.92K | 152.21K | 0.00 | 0.00 | 0.00 | 239.37K | 144.81K | 0.00 | 501.88K | 8.54K | 30.45K |
| Depreciation & Amortization | 305.95K | 323.14K | 347.61K | 378.75K | 333.84K | 2.94K | 15.25K | 25.76K | 25.88K | 110.14K | 662.55K | 2.10M | 2.93M | 2.94M | 2.84M | 2.02M | 1.80M | 2.52M |
| EBITDA | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | -1.51M | -3.22M | -3.12M | -2.61M | -1.71M | -13.79M | -24.87M | -28.05M | -30.56M | -39.86M | -19.55M | -33.26M | -17.99M |
| EBITDA Ratio | -634.16% | -1,417.83% | -519.59% | -327.42% | -515.18% | -23.52% | -644.10% | -17,979.05% | -6,488.51% | -1,998.26% | -15,026.90% | -20,542.67% | -990.78% | -1,547.10% | 1,112.94% | -72.92% | -6,833.66% | -380.48% |
| Operating Income | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | -1.42M | -3.24M | -3.13M | -3.87M | -1.80M | -14.46M | -27.01M | -30.97M | -33.60M | -43.05M | -24.87M | -37.62M | -20.90M |
| Operating Income Ratio | -637.42% | -1,442.61% | -531.70% | -338.88% | -536.92% | -23.57% | -647.15% | -18,059.88% | -9,597.64% | -2,103.69% | -15,756.97% | -22,306.25% | -1,097.02% | -1,700.93% | -1,052.47% | -92.78% | -7,726.28% | -441.03% |
| Total Other Income/Expenses | -274.93K | -284.01K | 154.00K | -615.33K | -176.45K | -220.17K | -45.35K | -19.79K | -1.56M | 748.35K | -3.23K | -8.41K | -167.17K | -47.56K | 85.75M | 2.81M | 2.54M | 355.32K |
| Income Before Tax | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | 42.69M | -22.07M | -35.09M | -20.54M |
| Income Before Tax Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | 1,043.62% | -82.32% | -7,205.50% | -433.53% |
| Income Tax Expense | 0.00 | 123.91K | 116.38K | 207.76K | 429.01K | 1.00 | 0.00 | 6.92K | 152.21K | -21.68K | 3.23K | -398.93K | 72.20K | 97.25K | 171.13M | 3.31M | 2.54M | 346.91K |
| Net Income | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | -42.69M | -22.07M | -35.09M | -20.54M |
| Net Income Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | -1,043.62% | -82.32% | -7,205.50% | -433.53% |
| EPS | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| EPS Diluted | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| Weighted Avg Shares Out | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
| Weighted Avg Shares Out (Dil) | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
Addex Announces Participation in the Bio-Europe 2023 Conference
Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will...
Addex Completes ADS Ratio Change
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the Company's previously disclosed change to...
Addex Announces Plan to Implement ADS Ratio Change
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
Addex led consortium wins Eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th...
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Cohort 1 is completed , and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based...
Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions First time mGlu5 linked to post - stroke functional recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 4, 202 3 - Addex Therapeutics...
Addex Therapeutics Ltd (ADXN) Q2 2023 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Transition Science Conference Call Participants...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
ADX71149 Phase 2 e pilepsy c linical s tudy Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation Indivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of committed research funding CHF 7.2 M...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim...
Source: https://incomestatements.info
Category: Stock Reports